Archived Investigations
Zoetis, Inc. (NYSE: ZTS)
Zoetis and certain of its executives are charged with failing to disclose material information during the Class Period concerning the growth, competitive positioning, market share, and veterinarian adoption of key products within the Companion Animal segment, violating federal securities laws.
The alleged false and misleading statements and/or omissions include, but are not limited to, that: (i) veterinarian prescription growth and adoption of the Company’s canine pain treatment, Librela, were stalling as clinicians became more cautious due to FDA safety warnings of serious neurological complications; (ii) Simparica Trio was losing significant market share to a lower priced competing canine parasiticide with broader indicated use in a slowing overall market; and (iii) the Company’s dermatology products, Apoquel and Cytopoint, were losing substantial market share to a newly launched competing canine treatment.
The case is City of Ann Arbor Retiree Health Care Benefit Plan & Trust v. Zoetis, Inc., No. 26-cv-04401.